Background In 1998, folic acid fortification of a large variety of cereal products became
mandatory in Canada, a country where the prevalence of neural-tube defects was historically …

Context In fall 2009 in Quebec, Canada, an immunization campaign was launched against
the 2009 influenza A(H1N1) pandemic strain, mostly using an AS03 adjuvant vaccine. By the …

… a , Gaston De Serres a b c , Nicole Boulianne a b , Brigitte Lefebvre d , Philippe De Wals
a b c … Évaluation de deux nouveaux vaccins pneumococciques conjugués pour l’immunisation …

Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …

… P De Wals has received research grants and reimbursements of travel expenses from vaccine
manufacturers including GlaxoSmithKline, Novartis, Sanofi Pasteur, and Pfizer, as well as …

Background The Canadian COVID-19 immunization strategy deferred second doses and
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…

Background: In Canada, a pneumococcal conjugate vaccine was licensed in 2001, and in
the province of Quebec, a publicly-funded program was implemented for high-risk children in …

… Philippe De Wals … Philippe De Wals … used to identify NTD cases, including a review of
hospital and outpatient clinic records (De Wals et al., 1999). From this survey, the Med-Echo file …

ContextMeningococcal polysaccharide vaccines are of limited effectiveness. New protein-polysaccharide
conjugate vaccines have yet to be evaluated in field conditions.ObjectiveTo …

Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving
invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies …